EP0003589A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Antacid tablet formulation
Assignee: Wellcome Foundation Ltd
•
Filing: 1979-02-05
•
Granted: —
•
Expires: 1999-02-05
Abstract
Abstract A dispersible tablet formulation comprising a conventional antacid component in an amount of from 50 to 90% by weight and a disintegrating agent having a swelling capacity of between 5 and 100 ml/g and in an amount of from 5 to 15% by weight.
Inventors
- 👤 David Harden
- 👤 Stephen Gayst
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-08 15:47
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/20; A61K9/2072; A61K9/2077; A61K33/00; A61K33/06; A61K33/08; A61K9/2004; A61K9/2022; A61K9/2027; A61K9/205; A61K9/2054; A61K9/2059
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
57 words
A tablet comprising a conventional antacid component as herein defined characterised in that the tablet is dispersible, the antacid component is present in an amount of from 50 to 90%, by weight, and the tablet additionally comprising from 5 to 15% by weight of a disintegrating agent having a swelling capacity of between 5 and 100 ml/g.
Claim 2
Dependent Claim
57 words
A tablet comprising a conventional antacid component as herein defined characterised in that the tablet is dispersible, the antacid component is present in an amount of from 50 to 90%, by weight, and the tablet additionally comprising from 5 to 15% by weight of a disintegrating agent having a swelling capacity of between 5 and 100 ml/g.
Claim 3
Dependent Claim
28 words
A dispersible tablet as claimed in claim 1 characterised in that the antacid component comprises a pharmaceutically acceptable metal base or alkaline salt thereof with a weak acid.
Claim 4
Dependent Claim
32 words
A dispersible tablet as claimed in either claim 1 or claim 2 characterised in that the antacid ccmponent has a solubility in water of less than 1 part by weight in 70.
Claim 5
Dependent Claim
28 words
A dispersible tablet as claimed in any one of claims 1 to 3 characterised in that the antacid component is a compound of calcium, bismuth, aluminium or magnesium.
Claim 6
Dependent Claim
26 words
A dispersible tablet as claimed in any one of claims 1 to 4 characterised in that the antacid component is a compound of calcium or magnesium.
Claim 7
Dependent Claim
35 words
A dispersible tablet as claimed in any one of claims 1 to 5 characterised in that the antacid component is selected from one or more of aluminium hydroxide magnesium hydroxide, magnesium carbonate and magnesium silicate.
Claim 8
Dependent Claim
33 words
A dispersible tablet as claimed in any one of claims 1 to 6 characterised in that the antacid component comprises aluminium hydroxide and magnesium hydroxide in a weight ratio of 4'1 to 1:4.
Claim 9
Dependent Claim
31 words
A dispersible tablet as claimed in any one of claims 1 to 7 characterised in that the antacid component has a weight median diameter, as herein defined, of less than 100pm.
Claim 10
Dependent Claim
19 words
A dispersible tablet as claimed in claim 8 characterised in that the weight median diameter is less than 50pm.
Claim 11
Dependent Claim
54 words
A dispersible tablet as claimed in any one of claims 1 to 9 characterised in that the disintegrating agent is selected from calcium carboxymethyl celluloses, low viscosity sodium carboxymethyl celluloses, guar based vegetable gums, a sodium alginate, cross-linked sodium carboxymethyl celluloses, cross-linked polyvinylpyrrolidones, low substituted hydroxypropyl celluloses, cation exchange resins and sodium starch glycolates.
Claim 12
Dependent Claim
24 words
A dispersible tablet as claimed in any one of claims 1 to 10 characterised in that the disintegrating agent is a sodium starch glycolate.
Claim 13
Dependent Claim
28 words
A dispersible tablet as claimed in any one of claims 1 to 11 characterised in that the disintegrating agent has a swelling capacity of less than 60 ml/g.
Claim 14
Dependent Claim
23 words
A dispersible tablet as claimed in any one of claims 1 to 11 characterised by comprising from 5 to 10% of disintegrating agent.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.